569 related articles for article (PubMed ID: 24639191)
41. Apoptosis-, proliferation, immune function-, and drug resistance- related genes in ER positive, HER2 positive and triple negative breast cancer.
Kolacinska A; Chalubinska J; Zawlik I; Szymanska B; Borowska-Garganisz E; Nowik M; Fendler W; Kubiak R; Pawlowska Z; Morawiec Z; Szemraj J
Neoplasma; 2012; 59(4):424-32. PubMed ID: 22489698
[TBL] [Abstract][Full Text] [Related]
42. Two histopathologically different diseases: hormone receptor-positive and hormone receptor-negative tumors in HER2-positive breast cancer.
Lee HJ; Park IA; Park SY; Seo AN; Lim B; Chai Y; Song IH; Kim NE; Kim JY; Yu JH; Ahn JH; Gong G
Breast Cancer Res Treat; 2014 Jun; 145(3):615-23. PubMed ID: 24820412
[TBL] [Abstract][Full Text] [Related]
43. The relevance of intrinsic subtype to clinicopathological features and prognosis in 4,266 Japanese women with breast cancer.
Shibuta K; Ueo H; Furusawa H; Komaki K; Rai Y; Sagara Y; Kamada Y; Tamaki N
Breast Cancer; 2011 Oct; 18(4):292-8. PubMed ID: 20571962
[TBL] [Abstract][Full Text] [Related]
44. Low protein expression of MET in ER-positive and HER2-positive breast cancer.
Zagouri F; Brandstetter A; Moussiolis D; Chrysikos D; Dimitrakakis C; Tsigginou A; Marinopoulos S; Zografos GC; Sergentanis TN; Dimopoulos MA; Filipits M
Anticancer Res; 2014 Mar; 34(3):1227-31. PubMed ID: 24596364
[TBL] [Abstract][Full Text] [Related]
45. Alpha- and beta-adrenergic receptor (AR) protein expression is associated with poor clinical outcome in breast cancer: an immunohistochemical study.
Powe DG; Voss MJ; Habashy HO; Zänker KS; Green AR; Ellis IO; Entschladen F
Breast Cancer Res Treat; 2011 Nov; 130(2):457-63. PubMed ID: 21298476
[TBL] [Abstract][Full Text] [Related]
46. Expression of androgen receptors in triple negative breast carcinomas.
Mrklić I; Pogorelić Z; Capkun V; Tomić S
Acta Histochem; 2013 May; 115(4):344-8. PubMed ID: 23031358
[TBL] [Abstract][Full Text] [Related]
47. Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers.
Castellano I; Allia E; Accortanzo V; Vandone AM; Chiusa L; Arisio R; Durando A; Donadio M; Bussolati G; Coates AS; Viale G; Sapino A
Breast Cancer Res Treat; 2010 Dec; 124(3):607-17. PubMed ID: 20127405
[TBL] [Abstract][Full Text] [Related]
48. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
Kim MJ; Ro JY; Ahn SH; Kim HH; Kim SB; Gong G
Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528
[TBL] [Abstract][Full Text] [Related]
49. Basal-like breast cancer defined by FOXC1 expression offers superior prognostic value: a retrospective immunohistochemical study.
Ray PS; Bagaria SP; Wang J; Shamonki JM; Ye X; Sim MS; Steen S; Qu Y; Cui X; Giuliano AE
Ann Surg Oncol; 2011 Dec; 18(13):3839-47. PubMed ID: 21424368
[TBL] [Abstract][Full Text] [Related]
50. Numb protein expression correlates with a basal-like phenotype and cancer stem cell markers in primary breast cancer.
Rennstam K; McMichael N; Berglund P; Honeth G; Hegardt C; Rydén L; Luts L; Bendahl PO; Hedenfalk I
Breast Cancer Res Treat; 2010 Jul; 122(2):315-24. PubMed ID: 19795205
[TBL] [Abstract][Full Text] [Related]
51. The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer.
Tang D; Xu S; Zhang Q; Zhao W
Med Oncol; 2012 Jun; 29(2):526-33. PubMed ID: 21519872
[TBL] [Abstract][Full Text] [Related]
52. Id4 protein is highly expressed in triple-negative breast carcinomas: possible implications for BRCA1 downregulation.
Wen YH; Ho A; Patil S; Akram M; Catalano J; Eaton A; Norton L; Benezra R; Brogi E
Breast Cancer Res Treat; 2012 Aug; 135(1):93-102. PubMed ID: 22538771
[TBL] [Abstract][Full Text] [Related]
53. Distribution and prognosis of molecular breast cancer subtypes defined by immunohistochemical biomarkers in a Spanish population-based study.
Puig-Vives M; Sánchez MJ; Sánchez-Cantalejo J; Torrella-Ramos A; Martos C; Ardanaz E; Chirlaque MD; Perucha J; Díaz JM; Mateos A; Machón M; Marcos-Gragera R
Gynecol Oncol; 2013 Sep; 130(3):609-14. PubMed ID: 23747837
[TBL] [Abstract][Full Text] [Related]
54. CORRELATION BETWEEN CLINICAL PATHOLOGY OF LUMINAL B BREAST CANCER AND DETERMINATION OF ESTROGEN RECEPTOR, PROGESTERONE RECEPTOR AND HER2 EXPRESSION COMBINED WITH NUCLEAR MORPHOLOGY.
Yin D; Wang YL; Wang YF; Yang L; Zhang L; Tang C; Xie W; Ma Y
J Biol Regul Homeost Agents; 2015; 29(3):579-87. PubMed ID: 26403396
[TBL] [Abstract][Full Text] [Related]
55. Differential impact of the expression of the androgen receptor by age in estrogen receptor-positive breast cancer.
Tokunaga E; Hisamatsu Y; Taketani K; Yamashita N; Akiyoshi S; Okada S; Tanaka K; Saeki H; Oki E; Aishima S; Oda Y; Morita M; Maehara Y
Cancer Med; 2013 Dec; 2(6):763-73. PubMed ID: 24403250
[TBL] [Abstract][Full Text] [Related]
56. [Roles of immunohistochemistry in prognostic assessment of basal-like breast cancer].
Liu H; Fan QH; Zhang ZH; Li X; Yu HP; Liu GZ; Meng FQ
Zhonghua Bing Li Xue Za Zhi; 2009 Jan; 38(1):23-8. PubMed ID: 19489221
[TBL] [Abstract][Full Text] [Related]
57. Prognostic relevance of androgen receptor detection in operable breast cancer.
Søiland H; Kørner H; Skaland I; Janssen EA; Gudlaugsson E; Varhaug JE; Baak JP; Søreide JA
J Surg Oncol; 2008 Dec; 98(7):551-8. PubMed ID: 18937259
[TBL] [Abstract][Full Text] [Related]
58. Breast cancer-specific survival by clinical subtype after 7 years follow-up of young and elderly women in a nationwide cohort.
Johansson ALV; Trewin CB; Hjerkind KV; Ellingjord-Dale M; Johannesen TB; Ursin G
Int J Cancer; 2019 Mar; 144(6):1251-1261. PubMed ID: 30367449
[TBL] [Abstract][Full Text] [Related]
59. Interferon-inducible guanylate binding protein (GBP2) is associated with better prognosis in breast cancer and indicates an efficient T cell response.
Godoy P; Cadenas C; Hellwig B; Marchan R; Stewart J; Reif R; Lohr M; Gehrmann M; Rahnenführer J; Schmidt M; Hengstler JG
Breast Cancer; 2014 Jul; 21(4):491-9. PubMed ID: 23001506
[TBL] [Abstract][Full Text] [Related]
60. Androgen receptor and metastasis-associated protein-1 are frequently expressed in estrogen receptor negative/HER2 positive breast cancer.
Zhao L; Niu F; Shen H; Liu X; Chen L; Niu Y
Virchows Arch; 2016 Jun; 468(6):687-96. PubMed ID: 27026268
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]